Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
about
DLC-1: a Rho GTPase-activating protein and tumour suppressorDLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanismsp120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activitiesThe phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liverInhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell linesOncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activitiesDeleted in liver cancer-1 (DLC1): an emerging metastasis suppressor geneCooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implicationsDLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinomaDLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activityInvolvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarityEffects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migrationMutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and functionDeleted in liver cancer protein family in human malignancies (Review)Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2ADLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanismDLC1: a significant GAP in the cancer genomeRole of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motilityDLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domainFull activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK)Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review)Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinomaSilencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cellsDlc1 interaction with non-muscle myosin heavy chain II-A (Myh9) and Rac1 activationHyaluronidase modulates inflammatory response and accelerates the cutaneous wound healingIdentification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.Hypermethylation of the DLC1 CpG island does not alter gene expression in canine lymphomaFunctional and topological properties in hepatocellular carcinoma transcriptome.Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinomaProteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissuesGenetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.miR-139-5p modulates cortical neuronal migration by targeting Lis1 in a rat model of focal cortical dysplasiaNuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivoSolution structure of the phosphotyrosine binding (PTB) domain of human tensin2 protein in complex with deleted in liver cancer 1 (DLC1) peptide reveals a novel peptide binding mode.Uncovering the rare variants of DLC1 isoform 1 and their functional effects in a Chinese sporadic congenital heart disease cohort.Significance of genetic variants in DLC1 and their association with hepatocellular carcinomaMaternal BMI as a predictor of methylation of obesity-related genes in saliva samples from preschool-age Hispanic children at-risk for obesityARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells.The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells.
P2860
Q23917637-B0953DAA-912C-4710-8EB2-089D9748E7E3Q24297480-EBC488D5-0A64-478F-8A42-93481F3A6A86Q24317735-CBB47E91-2066-44AE-B12C-DEB55EF5AFE4Q24338316-79B67912-BE87-4A23-BD37-0B31DDE52A08Q24645379-DEA9A622-0D98-42F2-8E33-1F1D50C5DEE2Q24678585-AF32F6D6-4454-4ACA-9B8A-389BF5513A3BQ24684712-B5EDB5BB-1791-48CD-A34F-7C0617957BB6Q27025409-B4F27A53-44A3-4AA3-9565-3781D72ED4BDQ28384501-00144780-008E-460B-9612-3BCF435E7424Q28384558-8B6906DE-C102-491F-9014-5432C2F14D41Q28385400-20AC7831-55F5-4C96-BCE1-4BCB97FA7EA8Q28385568-4204BB6A-31BE-4BEE-89B3-854072ADF96AQ28386240-198F1D48-353B-437F-8211-58A28DCA9E99Q28386547-96E4240B-DEFE-43CD-8FEE-E03A2D83B1AFQ28387011-5A24BCF3-FB43-47DD-8F29-07B24D56BDB1Q28387833-5AE235AF-1D3E-457C-9C81-176E85634BB1Q28387959-B15C3C5A-F54B-47E5-A0AA-4133E35815F2Q28390592-9E493BE1-B2B9-460B-8BAA-827E00225DEAQ28391398-D14540D6-76C7-4D02-AB35-D944A0388B4DQ28391564-EBCCDADB-0E57-4B15-98ED-847B91D651C2Q28392664-C2E40A7D-79B7-42B5-BD13-13C5861F5BE5Q28394917-D65D3A7C-19E2-41B5-AF82-57C6628AA1C9Q28395522-15F01C37-5A0B-465F-A6A0-A563E20EB78FQ28395799-6C9B15EC-477A-4956-BAF9-4ECD43FDECA4Q28395847-1181C0C1-4C59-4431-AC99-D6E7E64408A6Q28544929-AC44AE6F-6D6B-4FD4-8188-7D056BB556F9Q30447293-BE93C696-31D2-485D-A58E-86F04C23EBEAQ30884853-15690FC0-649E-4C6D-8C62-46EAE165CD7EQ31059884-1567F242-CCBD-40CF-BBE6-23CB5DEAABFEQ33354161-4F236802-A07F-4CAB-A664-DD1EF528E6E2Q33498165-7529FB0F-0F07-4D6B-A9A5-D61CDF03125FQ33559593-DA8A4DF5-A7D6-4B8B-9116-FCE34F9A435AQ33748429-3CDE841B-D3A5-4C4F-9844-E41E7113D196Q34038402-EEB8529D-8FE4-4E4F-809E-9FB67F10F3A5Q34285684-3C6A462D-0902-40DE-B2BA-5DBD2BAA3F3EQ35108861-480083EE-E38E-48B1-AE0C-DC1A0211FE1CQ35919725-94A641CB-EB78-4E2E-A4E4-BBD288B21EE4Q36244489-35A447AE-3C07-4D4F-BA51-58E8BB565348Q36774904-B3A291DF-5948-407E-8CD2-4DD745719D65Q37113195-6E491E79-D35A-4100-91B1-AA1205A9E335
P2860
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Rho GTPase-activating protein ...... n in hepatocellular carcinoma.
@en
type
label
Rho GTPase-activating protein ...... n in hepatocellular carcinoma.
@en
prefLabel
Rho GTPase-activating protein ...... n in hepatocellular carcinoma.
@en
P2093
P1433
P1476
Rho GTPase-activating protein ...... on in hepatocellular carcinoma
@en
P2093
Chun-Ming Wong
Dong-Yan Jin
Irene Oi-Lin Ng
Tai-On Yau
Thomas Ho-Yin Leung
Yick-Pang Ching
P304
P356
10.1158/0008-5472.CAN-05-1318
P407
P577
2005-10-01T00:00:00Z